Abstract
Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas.
Cancer Discov; 2(8); 666-9. ©2012 AACR.
MeSH terms
-
Animals
-
Carcinoma, Pancreatic Ductal / enzymology*
-
Cell Transformation, Neoplastic / metabolism*
-
Extracellular Signal-Regulated MAP Kinases / metabolism*
-
Humans
-
MAP Kinase Signaling System*
-
Mitogen-Activated Protein Kinase Kinases / metabolism*
-
Pancreatic Neoplasms / enzymology*
-
Proto-Oncogene Proteins B-raf / metabolism*
Substances
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Extracellular Signal-Regulated MAP Kinases
-
Mitogen-Activated Protein Kinase Kinases